Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

odanacatib

- PMLiVE

FDA approves clinical trial wearables

Greenlights Camntech's MotionWatch and Pro-Diary medical devices

- PMLiVE

Merck joins biosimilar Lantus race

Will work with Samsung to develop version of Sanofi's diabetes medicine

- PMLiVE

Merck cuts MK-3475 deals with Pfizer, Amgen and Incyte

Sees combination potential for cancer prospect

Novartis building

Novartis planning thousands more job cuts, says paper

NZZ am Sonntag claims pharma company plans to transfer roles to India

- PMLiVE

UCB to sell Biogen Idec’s MS drugs in Asia

Includes Tysabri and Tecfidera

Novartis building

CHMP denies Novartis’ heart failure drug

Panel refuses to recommend serelaxin for use in EU

Novartis building

CHMP backs Xolair for severe hives

Novartis set to expand indications for asthma drug

- PMLiVE

Amgen cholesterol antibody scores in another phase III trial

Evolocumab effective in patients who cannot take statins

Novartis building

New York plant set to close as Novartis continues cutbacks

More than 500 employees face the axe

- PMLiVE

Peacock steps down as Amgen CFO

Michael Kelly appointed acting financial head

- PMLiVE

Novartis cancer chief Hoppenot leaves for top job at Incyte

He ends 10-year spell at Swiss pharma giant

- PMLiVE

Pharma slammed by MPs for withholding trial data

Follows damning Tamiflu and data access report from UK's Public Accounts Committee

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links